ArticleHaematologica2014

Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function.

Denise Wolleschak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.